All patients
subjects at risk
chloroquine and derivatives in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.07 [0.95 ; 1.21 ] FACCT Trial, 2021, HYDRA (Hernandez-Cardenas), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 4 6% 7,037 moderate not evaluable deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Chen, 2020 0.56 [0.01; 30.20]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.09 [0.31; 3.84]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Galan, 2021 (REV) 1.06 [0.58; 1.95]
Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
HAHPS, 2020 7.00 [0.80; 60.90]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
ORCHID, 2020 1.07 [0.54; 2.11]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
TEACH, 2020 1.07 [0.34; 3.37]
1.07 [0.97 ; 1.19 ] Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 2021, Galan, 2021 (REV), Gonzalez (HCQ), 2020, HAHPS, 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020, TEACH, 2020 15 0% 8,938 moderate low deaths (time to event analysis only)detailed results Galan, 2021 (REV) 1.06 [0.58; 1.95]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.08 [0.98 ; 1.20 ] Galan, 2021 (REV), HYDRA (Hernandez-Cardenas), 2021, NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 5 0% 7,063 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
HAHPS, 2020 1.07 [0.63; 1.82]
TEACH, 2020 1.80 [0.62; 5.21]
1.20 [0.83 ; 1.72 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HAHPS, 2020, TEACH, 2020 3 0% 460 moderate not evaluable clinical improvementdetailed results Huang, 2020 1.37 [0.73; 2.56]
ORCHID, 2020 1.02 [0.73; 1.42]
1.09 [0.81 ; 1.46 ] Huang, 2020, ORCHID, 2020 2 0% 501 low not evaluable clinical improvement (14-day)detailed results Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
Huang, 2020 1.37 [0.73; 2.56]
ORCHID, 2020 1.02 [0.73; 1.42]
1.01 [0.78 ; 1.30 ] Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Huang, 2020, ORCHID, 2020 4 0% 982 low not evaluable clinical improvement (28-day)detailed results ORCHID, 2020 0.97 [0.69; 1.37]
0.97 [0.69 ; 1.37 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (7-day)detailed results ORCHID, 2020 1.16 [0.84; 1.61]
1.16 [0.84 ; 1.61 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
ORCHID, 2020 0.97 [0.69; 1.36]
0.94 [0.78 ; 1.14 ] FACCT Trial, 2021, HYDRA (Hernandez-Cardenas), 2021, ORCHID, 2020 3 0% 947 moderate not evaluable death or ventilationdetailed results Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
HYCOVID, 2020 1.12 [0.45; 2.79]
ORCHID, 2020 1.13 [0.60; 2.13]
RECOVERY, 2020 1.14 [1.03; 1.27]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
1.13 [1.03 ; 1.24 ] Gonzalez (HCQ), 2020, HYCOVID, 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 5 0% 6,570 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
HAHPS, 2020 0.91 [0.54; 1.54]
Huang, 2020 2.00 [1.15; 3.47]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
1.09 [0.82 ; 1.44 ] FACCT Trial, 2021, Gonzalez (HCQ), 2020, HAHPS, 2020, Huang, 2020, HYDRA (Hernandez-Cardenas), 2021 5 43% 645 moderate not evaluable mechanical ventilationdetailed results Galan, 2021 (REV) 7.21 [1.40; 37.04]
7.21 [1.40 ; 37.04 ] Galan, 2021 (REV) 1 0% 168 NA not evaluable radiologic improvement (14-day)detailed results Huang, 2020 1.33 [0.94; 1.88]
1.33 [0.94 ; 1.88 ] Huang, 2020 1 0% 22 NA not evaluable radiologic improvement (7-day)detailed results Huang, 2020 2.40 [0.26; 22.51]
2.40 [0.26 ; 22.51 ] Huang, 2020 1 0% 22 NA not evaluable viral clearance detailed results Huang, 2020 1.20 [0.78; 1.85]
1.20 [0.78 ; 1.85 ] Huang, 2020 1 0% 22 NA not evaluable viral clearance by day 14detailed results Chen, 2020 1.42 [0.26; 7.76]
Huang, 2020 1.09 [0.95; 1.26]
1.09 [0.95 ; 1.26 ] Chen, 2020, Huang, 2020 2 0% 55 moderate not evaluable viral clearance by day 7detailed results Huang, 2020 1.20 [0.60; 2.40]
1.20 [0.60 ; 2.40 ] Huang, 2020 1 0% 22 NA not evaluable ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
FACCT Trial, 2021 1.42 [0.79; 2.55]
Galan, 2021 (REV) 0.70 [0.33; 1.48]
1.00 [0.64 ; 1.58 ] Abd-Elsalam, 2020, FACCT Trial, 2021, Galan, 2021 (REV) 3 17% 616 moderate not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable serious adverse eventsdetailed results ORCHID, 2020 1.26 [0.56; 2.84]
1.26 [0.56 ; 2.84 ] ORCHID, 2020 1 0% 479 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
Huang, 2020 1.80 [0.14; 23.37]
ORCHID, 2020 1.42 [0.87; 2.34]
RECOVERY, 2020 1.36 [0.98; 1.90]
TEACH, 2020 1.16 [0.55; 2.42]
1.32 [1.03 ; 1.70 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Huang, 2020, ORCHID, 2020, RECOVERY, 2020, TEACH, 2020 5 0% 5,677 moderate not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-20 07:39 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 508,656,657,832
- roots T: 290
